Asuptegravir

N/A

Report date: 2025/12/23 14:20:27
NME

Base Information

Drug NameAsuptegravir
Drug Alias NameACC-017
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitors
TargetsHIV integrase
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Aidea Pharmaceutical Group Co LtdChengdu Aidi Medical Technology Co LtdNanjing Addy Medical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Aidi Medical Technology Co LtdNanjing Addy Medical Technology Co LtdShandong Yaoshi Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A